LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by UBS Group AG

UBS Group AG decreased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 24.0% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,889 shares of the medical instruments supplier’s stock after selling 1,858 shares during the period. UBS Group AG’s holdings in LeMaitre Vascular were worth $145,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Columbia Wanger Asset Management LLC boosted its position in shares of LeMaitre Vascular by 21.0% in the first quarter. Columbia Wanger Asset Management LLC now owns 1,093,903 shares of the medical instruments supplier’s stock valued at $26,943,000 after buying an additional 189,608 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of LeMaitre Vascular by 2.1% in the first quarter. Dimensional Fund Advisors LP now owns 927,465 shares of the medical instruments supplier’s stock valued at $22,843,000 after buying an additional 19,128 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of LeMaitre Vascular by 6.5% in the first quarter. Vanguard Group Inc. now owns 660,331 shares of the medical instruments supplier’s stock valued at $16,264,000 after buying an additional 40,448 shares in the last quarter. Conestoga Capital Advisors LLC bought a new position in shares of LeMaitre Vascular during the first quarter valued at about $9,549,000. Finally, Thomson Horstmann & Bryant Inc. boosted its position in shares of LeMaitre Vascular by 111.3% in the first quarter. Thomson Horstmann & Bryant Inc. now owns 359,339 shares of the medical instruments supplier’s stock valued at $8,850,000 after buying an additional 189,280 shares in the last quarter. Institutional investors own 67.10% of the company’s stock.

LeMaitre Vascular, Inc. (LMAT) traded up 0.70% during midday trading on Friday, reaching $32.98. 56,889 shares of the company traded hands. LeMaitre Vascular, Inc. has a one year low of $16.80 and a one year high of $36.09. The company has a 50 day moving average price of $30.93 and a 200-day moving average price of $27.31. The stock has a market capitalization of $627.35 million, a P/E ratio of 47.11 and a beta of 0.65.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.17 by $0.06. The business had revenue of $25.80 million for the quarter, compared to the consensus estimate of $25.42 million. LeMaitre Vascular had a net margin of 14.19% and a return on equity of 15.02%. The company’s revenue for the quarter was up 15.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.14 EPS. Analysts forecast that LeMaitre Vascular, Inc. will post $0.80 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Wednesday, August 23rd will be given a dividend of $0.055 per share. This represents a $0.22 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date is Monday, August 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 31.88%.

LeMaitre Vascular declared that its board has approved a share repurchase plan on Thursday, July 27th that allows the company to buyback $7.50 million in outstanding shares. This buyback authorization allows the medical instruments supplier to buy up to 1.4% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s board believes its stock is undervalued.

WARNING: “LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by UBS Group AG” was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/11/lemaitre-vascular-inc-nasdaqlmat-shares-sold-by-ubs-group-ag.html.

LMAT has been the topic of several research analyst reports. Zacks Investment Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $38.00 price target on the stock in a research report on Tuesday, August 1st. Benchmark Co. cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Monday, July 10th. They noted that the move was a valuation call. Stifel Nicolaus boosted their price target on shares of LeMaitre Vascular from $25.00 to $29.00 and gave the company a “buy” rating in a research report on Friday, April 28th. Canaccord Genuity cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating and set a $28.00 price target on the stock. in a research report on Monday, July 10th. Finally, Craig Hallum initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, June 6th. They set a “hold” rating and a $31.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $30.17.

In other LeMaitre Vascular news, Director Lawrence J. Jasinski sold 6,500 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $34.47, for a total transaction of $224,055.00. Following the transaction, the director now owns 12,863 shares of the company’s stock, valued at approximately $443,387.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Peter R. Gebauer sold 22,067 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $34.28, for a total transaction of $756,456.76. Following the transaction, the insider now directly owns 4,486 shares in the company, valued at approximately $153,780.08. The disclosure for this sale can be found here. Insiders have sold a total of 231,159 shares of company stock worth $7,662,007 in the last three months. Insiders own 23.70% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

What are top analysts saying about LeMaitre Vascular Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for LeMaitre Vascular Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit